These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 22467215)

  • 1. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.
    Thiel KW; Hernandez LI; Dassie JP; Thiel WH; Liu X; Stockdale KR; Rothman AM; Hernandez FJ; McNamara JO; Giangrande PH
    Nucleic Acids Res; 2012 Jul; 40(13):6319-37. PubMed ID: 22467215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer.
    Zhang L; Mu C; Zhang T; Wang Y; Wang Y; Fan L; Liu C; Chen H; Shen J; Wei K; Li H
    ACS Appl Mater Interfaces; 2020 Jul; 12(29):32360-32371. PubMed ID: 32613835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
    Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
    Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
    Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.
    Thiel WH; Thiel KW; Flenker KS; Bair T; Dupuy AJ; McNamara JO; Miller FJ; Giangrande PH
    Methods Mol Biol; 2015; 1218():187-99. PubMed ID: 25319652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
    Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
    Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX.
    Dastjerdi K; Tabar GH; Dehghani H; Haghparast A
    Biotechnol Appl Biochem; 2011; 58(4):226-30. PubMed ID: 21838796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
    Zhou J; Li H; Zhang J; Piotr S; Rossi J
    J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advance in the study of targeting delivery system for siRNA mediated by aptamers].
    Wang XL; Wang QQ; Song HF
    Yao Xue Xue Bao; 2012 Jul; 47(7):850-5. PubMed ID: 22993847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth.
    Mahlknecht G; Maron R; Mancini M; Schechter B; Sela M; Yarden Y
    Proc Natl Acad Sci U S A; 2013 May; 110(20):8170-5. PubMed ID: 23630281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.
    Yao YD; Sun TM; Huang SY; Dou S; Lin L; Chen JN; Ruan JB; Mao CQ; Yu FY; Zeng MS; Zang JY; Liu Q; Su FX; Zhang P; Lieberman J; Wang J; Song E
    Sci Transl Med; 2012 Apr; 4(130):130ra48. PubMed ID: 22517885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
    Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
    Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells.
    Zhou J; Tiemann K; Chomchan P; Alluin J; Swiderski P; Burnett J; Zhang X; Forman S; Chen R; Rossi J
    Nucleic Acids Res; 2013 Apr; 41(7):4266-83. PubMed ID: 23470998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection.
    Thiel WH; Bair T; Peek AS; Liu X; Dassie J; Stockdale KR; Behlke MA; Miller FJ; Giangrande PH
    PLoS One; 2012; 7(9):e43836. PubMed ID: 22962591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas.
    Sett A; Borthakur BB; Bora U
    Clin Transl Oncol; 2017 Aug; 19(8):976-988. PubMed ID: 28224267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy.
    Mahlknecht G; Sela M; Yarden Y
    Methods Mol Biol; 2015; 1317():3-15. PubMed ID: 26072398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aptamer-conjugated and doxorubicin-loaded grapefruit-derived nanovectors for targeted therapy against HER2
    Tang Z; Jun Y; Lv Y; Li Y; Zhang Z; Tao M; Chen X; He J; Zhang L; Wang QL
    J Drug Target; 2020 Feb; 28(2):186-194. PubMed ID: 31134823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.